MECHANISM OF ACTION
PT-141 (also called bremelanotide) is a peptide that acts on receptors in the brain's hypothalamus, the region that regulates sexual arousal and desire. This is completely different to how drugs like Viagra or Cialis work. Those drugs act on blood vessels in the body to improve physical response. PT-141 works upstream, in the brain itself, addressing the desire side of the equation rather than the physical mechanics. This is what makes it useful for people who have the brain's arousal signalling rather than blood flow. It was the first centrally-acting (brain-based) molecule of its kind to complete formal regulatory review, which is why it is well characterised in the literature.
RESEARCH APPLICATIONS
- Central melanocortin receptor (MC3R/MC4R) research
- Hypothalamic signalling pathway studies
- Comparative melanocortin pharmacology
- Receptor-selectivity research
RESEARCH HIGHLIGHTS
Central rather than peripheral pathway
2003Research distinguishes this molecule from vascular-acting compounds: laboratory work locates its activity at brain melanocortin receptors. Research observations only - not a statement about this product.
Ref: Molinoff et al.
Melanocortin receptor characterisation
2018Used in the literature as a reference agonist when mapping MC3R and MC4R behaviour.
Ref: Reviewed in Br J Pharmacol
RESEARCH PROTOCOL NOTES
Chemical Identity
Storage & Stability
Lyophilised: -20°C. Reconstituted: 2–8°C, 21 days. Protect from light. Approved auto-injector pens: room temperature storage.
Regulatory Status
Unscheduled in South Africa. Supplied for laboratory and research use only. Not a registered medicine, not evaluated by SAHPRA, not for human consumption. Not WADA prohibited.
Important - read before proceeding
This page is a summary of published scientific literature about a molecule. It is provided for research and educational purposes only. Nothing on this page is medical advice, a diagnosis, a recommendation, a prescription, or a claim that this compound treats, cures, prevents or improves any condition in humans. Research findings described here are observations reported by third-party researchers about the molecule - they are not statements about the product supplied by Bio Intelligence, and they should not be read as an expected outcome.
Compounds supplied are not registered medicines, have not been evaluated by SAHPRA, and are not for human consumption. No dosing, route of administration or usage guidance is provided by Bio Intelligence. If you have a health concern, speak to a registered healthcare practitioner.